During the corresponding time, Biodesix Inc recorded a revenue increase by 34.18 % year on year, sequentially revenue grew by 5.11 %. While revenue at the Biodesix Inc 's corporate clients
Biodesix Inc's Comment on Sales, Marketing and Customers
The company provides services to customers in the biopharmaceutical, life science, tools, and diagnostic sectors, including research, discovery, development, clinical trial testing, regulatory support, reimbursement, commercialization, and logistics across various cancer types and diseases. It collaborates with biopharmaceutical companies, academic research organizations, technology providers, and diagnostic companies through strategic partnerships. The company's diagnostic tests focus on lung disease, particularly lung cancer, supporting clinical decisions related to diagnosis, treatment, and monitoring. The lung cancer market in the United States offers over 10 million annual testing opportunities and exceeds $27 billion in annual market value. Key market segments include patients with lung nodules (approximately 5 to 6 million annually in the U.S.), primary care providers, and pulmonologists who assess lung cancer risk and determine treatment plans based on clinical and radiological factors. The company addresses clinical needs throughout the lung cancer continuum of care, from initial diagnosis to treatment guidance and disease progression monitoring.
Biodesix Inc’s Comment on Sales, Marketing and Customers
The company provides services to customers in the biopharmaceutical, life science, tools, and diagnostic sectors, including research, discovery, development, clinical trial testing, regulatory support, reimbursement, commercialization, and logistics across various cancer types and diseases. It collaborates with biopharmaceutical companies, academic research organizations, technology providers, and diagnostic companies through strategic partnerships. The company's diagnostic tests focus on lung disease, particularly lung cancer, supporting clinical decisions related to diagnosis, treatment, and monitoring. The lung cancer market in the United States offers over 10 million annual testing opportunities and exceeds $27 billion in annual market value. Key market segments include patients with lung nodules (approximately 5 to 6 million annually in the U.S.), primary care providers, and pulmonologists who assess lung cancer risk and determine treatment plans based on clinical and radiological factors. The company addresses clinical needs throughout the lung cancer continuum of care, from initial diagnosis to treatment guidance and disease progression monitoring.
Sources:
Biodesix Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Biodesix Inc’s corporate clients.
For your research, we’ve provided 9 tables on Biodesix Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
177.36 %